The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer
- Author(s)
- Bagguley, D; Harewood, L; McKenzie, D; Ptasznik, G; Ong, S; Chengodu, T; Woon, D; Sim, K; Sheldon, J; Lawrentschuk, N;
- Journal Title
- BJU International
- Publication Type
- Research article
- Abstract
- OBJECTIVES: Primary objectives: To determine the additive value of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the risk stratification of men with newly diagnosed prostate cancer (PCa) who would have otherwise been deemed suitable for active surveillance (AS). Specifically, we aim to determine if PSMA PET/CT can detect a cohort of men on AS that are in fact high risk and likely to experience unfavourable outcomes should they remain on their current treatment pathway. SECONDARY OBJECTIVES: to determine the additive value of PSMA PET/CT to repeat multiparametric magnetic resonance imaging (mpMRI) of the prostate and explore whether a confirmatory biopsy may be avoided in men with a negative PSMA PET/CT and a negative repeat mpMRI of the prostate (Prostate Imaging-Reporting and Data System score of <3). Furthermore, to develop a nomogram combining clinical, imaging and biomarker data to predict the likelihood of failure on AS in men with high-risk features. Also, a blood sample will be taken to perform a Prostate Health Index test at the time of confirmatory biopsy. Furthermore, a portion of this blood will be stored at a biobank for up to 5 years if a follow-up study on molecular biomarkers and genetic assays in this cohort of men is indicated, based on the results from the CONFIRM trial. PATIENTS AND METHODS: The CONFIRM trial is a prospective, multicentre, pre-test/post-test, cohort study across Victoria, Australia, involving men with newly diagnosed low-risk PCa with high-risk features, considered suitable for AS and undergoing confirmatory biopsy. The trial's goal is to provide high-quality evidence to establish whether PSMA PET/CT has a role in risk-stratifying men deemed suitable for AS despite having high-risk feature(s). RESULTS: The CONFIRM trial will measure the proportion of men deemed unsuitable for ongoing AS based on pathological upgrading and multidisciplinary team recommendation due to PSMA PET/CT scan and PSMA-targeted confirmatory biopsy. Additionally, the positive and negative predictive values, sensitivity, and specificity of PSMA PET/CT will be calculated in isolation and combined with repeat mpMRI of the prostate. CONCLUSIONS: This trial will provide robust prospective data to determine if PSMA-PET/CT and standard of care (prostate biopsy ± repeat mpMRI) can improve diagnostic certainty in men undergoing confirmatory biopsy for low-grade PCa with high-risk features.
- Publisher
- Wiley
- Keywords
- Humans; Male; Cohort Studies; Follow-Up Studies; *Positron Emission Tomography Computed Tomography/methods; Prospective Studies; Prostate/pathology; *Prostatic Neoplasms/diagnostic imaging/therapy/pathology; Victoria; Watchful Waiting; 18F‐DCFPyL; active surveillance; imaging; needle biopsy; positron emission tomography; prostate‐specific membrane antigen; prostatic neoplasm
- Department(s)
- Surgical Oncology
- Publisher's Version
- https://doi.org/10.1111/bju.16214
- Open Access at Publisher's Site
https://doi.org/10.1111/bju.16214- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-06-27 06:31:36
Last Modified: 2024-06-27 06:46:54